After Closing 2nd Venture Capital Round OGeS Expands, Hopes For More Deals | GenomeWeb

As GeneProt is about to close its doors for good (see related story), Oxford Genome Sciences is trying to rise from the ashes of Oxford GlycoSciences.

Last week, the Abingdon, UK-based company said it closed a second round of venture capital funding, following a first round last July. South East Growth Fund, a regional fund representing a number of institutional investors, was a lead investor in both financing rounds, and was joined this time by Oxford Capital Partners.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.